Glycorex Transplantation AB (publ)

NGM:GTAB B Stock Report

Market Cap: SEK 125.9m

Glycorex Transplantation Past Earnings Performance

Past criteria checks 0/6

Glycorex Transplantation's earnings have been declining at an average annual rate of -50.9%, while the Medical Equipment industry saw earnings growing at 22.9% annually. Revenues have been declining at an average rate of 2.1% per year.

Key information

-50.9%

Earnings growth rate

-51.1%

EPS growth rate

Medical Equipment Industry Growth6.2%
Revenue growth rate-2.1%
Return on equity-72.7%
Net Margin-89.1%
Next Earnings Update28 Nov 2024

Recent past performance updates

Recent updates

Read This Before Buying Glycorex Transplantation AB (publ) (NGM:GTAB B) Shares

Feb 12
Read This Before Buying Glycorex Transplantation AB (publ) (NGM:GTAB B) Shares

How Much Is Glycorex Transplantation's (NGM:GTAB B) CEO Getting Paid?

Dec 21
How Much Is Glycorex Transplantation's (NGM:GTAB B) CEO Getting Paid?

Revenue & Expenses Breakdown

How Glycorex Transplantation makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NGM:GTAB B Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2431-28330
31 Mar 2431-30350
31 Dec 2330-30370
30 Sep 2332-16360
30 Jun 2335-11360
31 Mar 2337-9340
31 Dec 2237-9320
30 Sep 2235-11310
30 Jun 2234-10290
31 Mar 2231-11290
31 Dec 2129-12290
30 Sep 2130-11290
30 Jun 2130-9290
31 Mar 2125-14280
31 Dec 2029-8260
30 Sep 2030-5250
30 Jun 2032-2240
31 Mar 20375230
31 Dec 19407240
30 Sep 19417250
30 Jun 19384410
31 Mar 19384350
31 Dec 18383290
30 Sep 1836-12500
30 Jun 1836-13290
31 Mar 1837-14290
31 Dec 1735-16290
30 Sep 1738-1310
30 Jun 1737-1310
31 Mar 1737-1310
31 Dec 16391310
30 Sep 1637-2340
30 Jun 1638-3340
31 Mar 1637-4340
31 Dec 1535-7340
30 Sep 1537-4340
30 Jun 1538-2340
31 Mar 1539-3340
31 Dec 1439-3340
30 Sep 1438-5320
30 Jun 1437-5320
31 Mar 1436-5320
31 Dec 1335-6320

Quality Earnings: GTAB B is currently unprofitable.

Growing Profit Margin: GTAB B is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GTAB B is unprofitable, and losses have increased over the past 5 years at a rate of 50.9% per year.

Accelerating Growth: Unable to compare GTAB B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GTAB B is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31%).


Return on Equity

High ROE: GTAB B has a negative Return on Equity (-72.65%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies